Cherwell makes an impact with new continuous monitoring microbial air samplers
ImpactAir high performance air sampler range joins Cherwell’s portfolio of cleanroom microbiology products.
Cherwell Laboratories has signed a distribution agreement with Pinpoint Scientific for the ImpactAir range of microbial air samplers. The new ImpactAir range of high performance microbial air samplers has been designed to meet the demanding environmental monitoring requirements of aseptic processing in the pharmaceutical and healthcare industries.
ImpactAir is a state-of-the-art range of slit-to-agar microbial air samplers that fully complements Cherwell’s existing portfolio of environmental monitoring products, including SAS microbial air samplers and Redipor prepared microbiological media range. Whereas SAS samplers are ideal for rapid and frequent routine sampling regimes, ImpactAir is designed for continuous monitoring in high-grade areas where in-process sampling of viable particles is critical. Due to its unique design, ImpactAir does not shed particles, so it can be used alongside particle counting devices, and as it runs with extremely low levels of vibration, it can also be operated near balances.
By using larger 140-mm petri dishes, such as those in the Redipor range, the ImpactAir can continuously sample to a single dish over longer periods. This sampling time can be easily programmed on the touch screen user interface, from minutes up to several hours, depending on the process to be monitored. The petri dish rotates slowly under the inlet slit to present fresh agar throughout– dramatically reducing the probability of ‘twin impingement’ (where two microbes impact on an agar plate at the same point to incubate as a single colony) for enhanced accuracy and enabling an estimate of any event times during key processes.
ImpactAir is the first sampler of its kind to employ precision sensing and control to automatically adjust and maintain the distance between air inlet and agar surface, further enhancing sampling efficiency. Critically, this ensures a consistent d50 value of <0.5µm is maintained throughout an entire sampling run, as independently verified by Public Health England (PHE) following physical and biological validation.
Andy Whittard, Cherwell’s Managing Director, commented, “The new ImpactAir microbial air sampler is an exciting addition to our ‘cleanroom microbiology solutions’ offering. It fully supports our existing portfolio of quality environmental monitoring products for our pharma customers. Effective viable monitoring within high-grade areas is vitally important and ImpactAir allows users to perform high efficiency, continuous environmental monitoring. We look forward to working with the manufacturer, Pinpoint Scientific, in developing the UK and Irish markets.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance